CClinicalTrials.gg
Sign In
Status unknownNCT04185025Updated Dec 4, 2019

Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers

An interventional study of Ceramides in CeraVe Moisturising Lotion, sponsored by Peking University First Hospital. Status unknown at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-12-04.

Sponsored by Peking University First Hospital · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Nov 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

This study aims to evaluate the improvement of CeraVe moisturising lotion on the cuticle moisture of dry skin and barrier repair function.

02

Conditions studied

  • CeraVe Moisturising Lotion
03

In context

Lead sponsor

Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Those who volunteer to participate in the trial, sign the informed consent, be able to cooperate with follow-up observation, and conduct the trial according to the guidance of the doctor.
  • Dry skin subjects with symmetrical distribution of forearm flexion diagnosed by a doctor.
  • Those who are 30-80 years old, male or female.
  • Those with good compliance who can not use other external drugs during the entire observation period.

Exclusion criteria

Exclusion Criteria:

  • Those who do not sign the informed consent.
  • Those with the history of allergies to test product and control product ingredients.
  • Those who received or are receiving medical or physical therapy for any skin or systemic disease recently (≤3 months)
  • Those who have a large amount of exudation in the acute phase or who are infected at the test site.
  • Female subjects who are preparing for pregnancy, pregnancy, lactation, or within six months after delivery.
  • Those who participate in clinical trials of other moisturizing products or emollients.
  • Those who are taking other oral medicines that affect the skin condition.
  • Those who the investigator considers unsuitable for other reasons.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CeraVe Moisturising Lotion

    Drug: Ceramides

  • Active comparator
    Half Mu ceramide body milk

    Drug: Ceramides

Interventions

  • DrugCeramides

    On the 0th day, it is determined that one of the leg extensions of the participant is the test side using CeraVe Moisturising Lotion and the opposite side is the control side using Half Mu ceramide body milk by the random table. Participants are required to use the product in the morning and evening according to the "Product Use Procedures", during which other moisturizing products or emollients are prohibited. And the follow-up tests are conducted at the prescribed time. At each visit, empty packaging of products used during this period must be collected; if they are not used up as required, the remaining products must be collected.

06

What researchers measure

Primary outcomes

  1. Self-assessment from patients

    The patients fill out questionnaires and score erythema, desquamation, dryness, itching, and cleft palate on both sides of the calves (0 = none, 1 = light, 2 = medium, 3 = severe).

    Time frame: 17 days

Secondary outcomes

  1. The loss of transdermal water

    The percutaneous water loss value of the test site is measured continuously in an open chamber with Tewameter (TM300, Courage and Khazaka, Germany), and the measurement is performed 3 times continuously. The average value is taken after the value is stable.

    Time frame: 0 day, 1 day, 7 days, 14 days, 17 days

  2. Cuticle moisture

    The water content in the stratum corneum of the test site is measured 5 times with Corneometer (CM825, Course and Khazaka, Germany) and the average value is taken.

    Time frame: 0 day, 1 day, 7 days, 14 days, 17 days

07

Study locations

1 of 1 sites recruiting
  • Peking University First Hospital
    Beijing, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04185025
Lead sponsor
Peking University First Hospital
Responsible party
Yan Wu (Professor, Peking University First Hospital) — Principal investigator
First posted
Dec 4, 2019
Start date
Sep 20, 2019
Primary completion
Dec 2019 (estimated)
Completion
Jan 2020 (estimated)
Last update
Dec 4, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Peking University First Hospital

Start the discussion